Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats

American Journal of Hypertension

Volumn 25, Issue 5, 2012, Pages 604-611

  Sofue, Tadashi ^a   Kiyomoto, Hideyasu ^b   Kobori, Hiroyuki ^c,d   Urushihara, Maki ^d   Nishijima, Yoko ^a   Kaifu, Kumiko ^a   Hara, Taiga ^a   Matsumoto, Sachiko ^b   Ichimura, Atsuhiko ^b   Ohsaki, Hiroyuki ^e   Hitomi, Hirofumi ^c   Kawachi, Hiroshi ^f   Hayden, Melvin R ^g   Whaley Connell, Adam ^g   Sowers, James R ^g   Ito, Sadayoshi ^b   Kohno, Masakazu ^a   Nishiyama, Akira ^c  

^a KAGAWA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e EHIME PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^f NIIGATA UNIVERSITY   (Japan)

^g University of Missouri   (United States)

Author keywords

angiotensin II receptor blockers (ARBs); blood pressure; hypertension; juxtamedullary glomeruli; microalbuminuria; olmesartan; type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ANGIOTENSIN II; CREATININE; DESMIN; GLUCOSE; GLYCOSYLATED ALBUMIN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INSULIN; MESSENGER RNA; NEPHRIN; OLMESARTAN; PODOCIN; RESERPINE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EARLY INTERVENTION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INTRAABDOMINAL FAT; JUXTAMEDULLARY GLOMERULAR PODOCYTE INJURY; KIDNEY MASS; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IMIDAZOLES; JUXTAGLOMERULAR APPARATUS; MALE; MEMBRANE PROTEINS; PODOCYTES; RATS; RATS, INBRED OLETF; RESERPINE; TETRAZOLES;

EID: 84859910851     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2012.1     Document Type: Article

References (38)

1. Makino H, Nakamura Y, Wada J. Remission and regression of diabetic nephropathy. Hypertens Res 2003; 26:515-519. (Pubitemid 36974992)
2. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356-360. (Pubitemid 14179541)
3. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951. (Pubitemid 39447135)
4. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271:275-279. (Pubitemid 24030753)
5. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24:11-25. (Pubitemid 41818080)
6. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678. (Pubitemid 34851925)
7. Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, Torella R, Cozzolino D. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized doubleblind placebo-controlled crossover study. Diabetes Care 2002; 25:1909-1913. (Pubitemid 41071043)
8. Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med 2003; 139:90-96.
9. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30:1577-1578. (Pubitemid 46871174)
10. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005;16:703-711. (Pubitemid 41725107)
11. Nishiyama A, Nakagawa T, Kobori H, Nagai Y, Okada N, Konishi Y, Morikawa T, Okumura M, Meda I, Kiyomoto H, Hosomi N, Mori T, Ito S, Imanishi M. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J Hypertens 2008; 26:1849-1859.
12. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
13. Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Januszewicz A. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24:403-408. (Pubitemid 43348255)
14. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907-917.
15. Sakoda M, Ichihara A, Kurauchi-Mito A, Narita T, Kinouchi K, Murohashi-Bokuda K, Saleem MA, Nishiyama A, Suzuki F, Itoh H. Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Am J Hypertens 2010; 23:575-580.
16. Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, Ohashi N, Nakano D, Hitomi H, Imanishi M. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 2010; 332:1072-1080.
17. Blanco S, Vaquero M, Gómez-Guerrero C, López D, Egido J, Romero R. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens 2005; 18:557-565.
18. Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fatty rats. Hypertension 1997; 29:728-735. (Pubitemid 27097977)
19. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41:1422-1428.
20. Uehara Y, Hirawa N, Kawabata Y, Numabe A, Gomi T, Ikeda T, Omata M. Angiotensin II subtype-1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non-insulin-dependent diabetes mellitus. Am J Hypertens 1999;12:21-27. (Pubitemid 29118225)
21. Wienen W, Richard S, Champeroux P, Audeval-Gerard C. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J Renin Angiotensin Aldosterone Syst 2001; 2:31-36. (Pubitemid 33687416)
22. Sofue T, Kiyomoto H. Angiotensin II receptor blocker is a renoprotective remedy for metabolic syndrome. Hypertens Res 2009; 32:735-737.
23. Mori T, Cowley AW Jr, Ito S. Molecular mechanisms and therapeutic strategies of chronic renal injury: physiological role of angiotensin II-induced oxidative stress in renal medulla. J Pharmacol Sci 2006; 100:2-8. (Pubitemid 43161607)
24. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69:2131-2147. (Pubitemid 43882099)
25. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54:1626-1634. (Pubitemid 40770751)
26. Kim JJ, Li JJ, Jung DS, Kwak SJ, Ryu DR, Yoo TH, Han SH, Choi HY, Kim HJ, Han DS, Kang SW. Differential expression of nephrin according to glomerular size in early diabetic kidney disease. J Am Soc Nephrol 2007; 18:2303-2310.
27. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, Camussi G. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52:1023-1030. (Pubitemid 36384273)
28. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P, Endlich K. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 2001; 12:413-422. (Pubitemid 32180009)
29. Miceli I, Burt D, Tarabra E, Camussi G, Perin PC, Gruden G. Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone. Am J Physiol Renal Physiol 2010; 298:F381-F390.
30. Hoffmann S, Podlich D, Hähnel B, Kriz W, Gretz N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004; 15:1475-1487. (Pubitemid 38679672)
31. Suzuki K, Han GD, Miyauchi N, Hashimoto T, Nakatsue T, Fujioka Y, Koike H, Shimizu F, Kawachi H. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 2007; 170:1841-1853. (Pubitemid 47339259)
32. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366:2026-2033. (Pubitemid 41773378)
33. Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 2007; 30:325-334. (Pubitemid 46804317)
34. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Johnson RJ, Croker B. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007; 18:539-550. (Pubitemid 46193319)
35. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005; 288:F1144-F1152. (Pubitemid 40677084)
36. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59:251-287. (Pubitemid 47481436)
37. Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Oda T, Suzuki S, Miura S. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 2007; 192:595-603. (Pubitemid 46455962)
38. Mizukawa M, Ohmori K, Obayashi A, Ishihara Y, Yoshida J, Noma T, Yukiiri K, Kosaka H, Kohno M. Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model. Hypertens Res 2009; 32:617-624.